Valuation: Cartesian Therapeutics, Inc.

Market Cap 28Cr 24Cr 22Cr 20Cr 39Cr 2.66TCr 39Cr 263.7Cr 103.33Cr 1.33TCr 104.28Cr 102.02Cr 4.43TCr P/E 2026 *
-3.07x
P/E 2027 * -2.21x
Enterprise Value 14Cr 12Cr 11Cr 10Cr 19Cr 1.31TCr 19Cr 129.83Cr 51Cr 655.03Cr 51Cr 50Cr 2.18TCr EV / Sales 2026 *
361x
EV / Sales 2027 * -47.8x
Free-Float
47.87%
Yield 2026 *
-
Yield 2027 * -
1 day+3.85%
1 week+4.79%
Current month+17.69%
1 month+11.14%
3 months+24.39%
6 months+36.00%
Current year+27.32%
1 week 8.47
Extreme 8.47
9.53
1 month 7.27
Extreme 7.27
9.53
Current year 5.6
Extreme 5.6
11
1 year 5.6
Extreme 5.6
11.8
3 years 5.6
Extreme 5.6
42.6
5 years 5.6
Extreme 5.6
42.6
10 years 5.6
Extreme 5.6
42.6
Date Insider Type Main position Quantity % Market Cap.
06/01/26 Sell

Chief Technology Officer

3,573 0.0137%
06/01/26 Sell

Chief Executive Officer

23,766 0.0914%
06/01/26 Sell

Chief Financial Officer

10,591 0.0407%
Change 5-day change 1-year change 3-year change Capi.($)
+3.85%+4.79%-18.98% - 28Cr
+4.80%+3.44%+70.64%+109.32% 7.33TCr
-0.84%+13.22%+47.89%+88.99% 6.2TCr
+3.70%-4.77%+0.41%+484.07% 2.8TCr
+5.24%+5.65%+56.71%+21.30% 2.41TCr
-1.60%-1.29%-19.31%-19.10% 2.3TCr
-6.00%+6.02%+244.39%+430.80% 1.83TCr
+0.57%+6.52%+40.83%-13.52% 1.95TCr
+3.83%+2.65%+21.42%+557.58% 1.59TCr
+2.11%-1.21%+36.57%+149.14% 1.3TCr
Average +1.57%+1.43%+48.06%+200.95% 2.77TCr
Weighted average by Cap. +1.74%+3.14%+54.68%+164.62%

Financials

2026 *2027 *
Net sales 4L 3L 3L 3L 5L 3.63Cr 5L 36.01L 14.11L 1.82Cr 14.24L 13.93L 6.04Cr 2L 2L 2L 2L 3L 2.39Cr 4L 23.74L 9L 1.2Cr 9L 9L 3.98Cr
Net income -8.74Cr -7.55Cr -7.08Cr -6.45Cr -12Cr -836.07Cr -12Cr -83Cr -33Cr -418.87Cr -33Cr -32Cr -1.39TCr -14Cr -12Cr -12Cr -11Cr -20Cr -1.37TCr -20Cr -135.69Cr -53Cr -684.61Cr -54Cr -52Cr -2.28TCr
Net Debt -14Cr -12Cr -11Cr -10Cr -20Cr -1.35TCr -20Cr -133.87Cr -52Cr -675.42Cr -53Cr -52Cr -2.25TCr -29Cr -25Cr -23Cr -21Cr -40Cr -2.77TCr -41Cr -275.05Cr -107.78Cr -1.39TCr -108.76Cr -106.41Cr -4.62TCr
Logo Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc. is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.
Employees
75
Date Price Change Volume
17/26/17 $9.180 +3.85% 1,08,703
14/26/14 $8.840 +1.38% 86,398
13/26/13 $8.720 +0.52% 57,214
12/26/12 $8.675 +1.05% 74,749
11/26/11 $8.585 -2.00% 74,762
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
9.180USD
Average target price
34.57USD
Spread / Average Target
+276.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RNAC Stock